A new oral agent that was designed to selectively inhibit vascular endothelial growth factor (VEGF) receptors 1, 2 and 3 may benefit patients with advanced renal cell carcinoma who have failed a first-line systemic therapy. John Schieszer has the story in today’s Medical Minute.


Continue Reading